larization option. The site also includes a detailed tutorial on the use of the SYNTAX Score calculator, including definitions and example cases, together with SYNTAX data presentations and publications.
"The SYNTAX Score website will be an important tool to assist with revascularization strategies in these complex patient populations," said Patrick W. Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University, Rotterdam, The Netherlands, and chairman of the SYNTAX trial steering committee. "Having a consistent grading system for lesion complexity and severity of coronary artery disease allows me to better evaluate treatment options for my patients. The website's interactive calculator makes it easier to determine a patient's score and to reference current clinical data from the SYNTAX trial associated with that score."
The SYNTAX trial will continue to provide important data throughout the life of the trial (one-, three- and five-year outcomes). As more data become available, awareness and understanding of the SYNTAX trial will increase as will the utility of the SYNTAX Score.
"Boston Scientific is pleased to contribute the SYNTAX trial data to the advancement of evidence-based medicine," said Keith D. Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "The patients enrolled in SYNTAX have exceptionally complex anatomy and advanced disease, representing an unprecedented study group for a stent trial. Ongoing findings from this study will continue to be used to enhance the value of the SYNTAX Score in this high-risk patient population."
Boston Scientific will be announcing subset data analyses from the SYNTAX trial this week at EuroPCR.
The SYNTAX Score and SYNTAX Score website were developed under the direction of the SYNTAX trial steering committee, chaired by Dr. Serruys and F.W. Mohr, M.D., Ph.D., and were made po
Page: 1 2 3 4 Related biology technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2009 PR Newswire.
All rights reserved
. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital2
. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients3
. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions4
. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University5
. UMass Boston Opens Venture Development Center to Expand R&D Activity6
. Boston Scientific Announces First Quarter Special Items7
. Boston Scientific Launches New Coronary Imaging Catheter8
. Moodys Raises Boston Scientifics Rating Outlook to Stable9
. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University10
. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston11
. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory